Abstract

Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19+B-cell repopulation

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call